research SIDE EFFECTS OF CYCLOSPORINE COMPARED TO TACROLIMUS AMONG YEMENI KIDNEY TRANSPLANT PATIENTS WHO SHARE THE SAME ADJUVANT AGENTS: MYCOPHENOLATE MOFETIL AND PREDNISONE
Tacrolimus is a better option than cyclosporine due to fewer side effects.
Search
for
Sort by
Research
540-570 / 1000+ results
research Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
Stopping and restarting JAK inhibitors during pregnancy in women with alopecia areata leads to hair loss and regrowth, with most pregnancies resulting in healthy babies.
research Baricitinib for alopecia areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
research Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population
Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
research Blocking Potassium Channels (Kv1.3): A New Treatment Option for Alopecia Areata?
Kv1.3 blockers may help treat alopecia areata and promote hair regrowth.
research Are Janus kinase (JAK) inhibitors beneficial in the treatment of androgenic alopecia?
JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.
research Treatment of alopecia areata with the janus kinase inhibitor upadacitinib: A retrospective cohort study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research The JAK/STAT signaling pathway: from bench to clinic
The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.
research A humanized IL-2 fusion protein enhances T regulatory cells in vivo and restrains disease in a murine model of Alopecia Areata 4760
A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.
research A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab
Adalimumab helped control a child's severe eye disease when other treatments failed.
research Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
research Perspectives of Chinese Adult Patients with Alopecia Areata on Janus Kinase Inhibitors Therapy: A Qualitative Analysis Based on Social Media Platforms
Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.
research Ketoconazole-p Aminobenzoic Cocrystal Exhibits a Potent Anti-inflammatory Effect on the Skin of BALBc Mice
The new cocrystal KET-PABA is a more effective and safe anti-inflammatory treatment for skin conditions in mice.
research Case Report of a Patient With Psoriasis Vulgaris, Psoriatic Arthritis and Alopecia Universalis Successfully Treated With Tofacitinib and Methotrexate
Tofacitinib and methotrexate successfully treated a woman's severe skin, joint, and hair loss issues.
research Anticytokine therapy, particularly anti-IFN-γ, in Th1-mediated autoimmune diseases
Blocking interferon-gamma might help treat various autoimmune diseases.
research 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
Cancer treatment drugs can cause permanent hair loss by damaging hair follicle stem cells, but a specific inhibitor might reverse this effect.
research Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
research Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with AIRE gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
Ruxolitinib helped a patient with alopecia areata regrow hair.
research Emerging drugs for alopecia areata: JAK inhibitors
JAK inhibitors may soon be a safe and effective treatment for alopecia areata.
research Successful hair regrowth in an acute diffuse form of alopecia areata during oral tacrolimus treatment in a patient with rheumatoid arthritis
Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
research ALOPECIA AREATA: ASPECTOS FISIOLÓGICOS E AVANÇOS TERAPÊUTICOS – UMA REVISÃO DE LITERATURA
JAK inhibitors show promise for treating Alopecia Areata, but more research is needed for better, accessible treatments.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients.
Baricitinib is effective and safe for treating severe alopecia areata.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research Editor's Picks August 2023
Anti-IL17A therapy reduced venous leg ulcer size by 64% without major side effects.
research Acne keloidalis nuchae in renal transplant patients receiving tacrolimus and sirolimus
Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.
research 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
research Rapidly progressive alopecia areata totalis in a COVID‐19 patient, unresponsive to tofacitinib
A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
research SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
Entospletinib effectively prevents eye and skin GVHD in mice.